28 Apr, 09:54 - Indian

SENSEX 79771.72 (0.71)

Nifty 50 24196.8 (0.65)

Nifty Bank 55161.75 (0.91)

Nifty IT 35228.45 (-0.94)

Nifty Midcap 100 53978.75 (0.76)

Nifty Next 50 64780.5 (0.72)

Nifty Pharma 21754.8 (1.27)

Nifty Smallcap 100 16607.4 (0.36)

28 Apr, 09:54 - Global

NIKKEI 225 35860.85 (0.43)

HANG SENG 22022 (0.19)

S&P 5533.5 (-0.51)


Hot Pursuit News

You are Here : Home > News > Hot Pursuit News >

(25 Feb 2025, 16:03)

Gland Pharma’s Visakhapatnam facility gets 3 USFDA observations

Gland Pharma has announced that the United States Food and Drug Administration (USFDA) conducted a Pre-Approval Inspection (PAI) for Sterile Active Pharmaceutical Ingredients (APIs) at its facility in JNPC, Visakhapatnam, Andhra Pradesh.


The inspection was conducted from 19 February 2025 to 25 February 2025.

At the conclusion of the inspection, the USFDA issued a Form 483 with three observations. The company stated that these observations are procedural in nature, and it plans to submit corrective and preventive actions to the USFDA within the required time frame.

The company further clarified that the observations are not repeated and are unrelated to any data integrity concerns.

Gland Pharma is one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India.

Gland Pharma’s consolidated net profit increased 6.67% to Rs 204.70 crore despite 10.42% decline in revenue from operations to Rs 1,384.1 crore in Q3 FY25 over Q3 FY25.

The scrip rallied 4.62% to settle at Rs 1,595.50 on the BSE.

More News
More Company News View Company Information

Capital Market Publishers India Pvt. Ltd

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071, India.

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

Copyright @ Capital Market Publishers India Pvt.Ltd

Designed, Developed and maintained by CMOTS Infotech (ISO 9001:2015 Certified)

Site best viewed in Internet Explorer Edge ,   Google Chrome 115.0.5790.111 + ,   Mozilla Firefox 115.0.3 + ,   Opera 30.0+, Safari 16.4.1 +